Metformin in Breast Cancer: Time for Action
- 10 July 2009
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (20), 3271-3273
- https://doi.org/10.1200/jco.2009.22.1630
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast CancerJournal of Clinical Oncology, 2009
- Targeting AMPK: A new therapeutic opportunity in breast cancerCritical Reviews in Oncology/Hematology, 2008
- Insulin in the Adjuvant Breast Cancer Setting: A Novel Therapeutic Target for Lifestyle and Pharmacologic Interventions?Journal of Clinical Oncology, 2008
- AMP-Activated Protein Kinase in Metabolic Control and Insulin SignalingCirculation Research, 2007
- 4E-Binding Protein 1, A Cell Signaling Hallmark in Breast Cancer that Correlates with Pathologic Grade and PrognosisClinical Cancer Research, 2007
- PIK3CA mutations in breast cancer are associated with poor outcomeBreast Cancer Research and Treatment, 2005
- Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast CancersClinical Cancer Research, 2004
- The PIK3CA gene is mutated with high frequency in human breast cancersCancer Biology & Therapy, 2004
- TSC2 Mediates Cellular Energy Response to Control Cell Growth and SurvivalCell, 2003
- Role of AMP-activated protein kinase in mechanism of metformin actionJCI Insight, 2001